[Effects of Spasfon on course of labor].
OBJECTIVE
To observe the effects of Spasfon on improving dilatation of cervix and promoting the progression of labor.


METHODS
Ninety seven normal primiparae with cervical edema were randomly divided into Spasfon group (group A, n = 46) and atropine group (group B, n = 51) when the cervix dilated 2 - 3 cm. Group A was given 80 mg of Spasfon intravenously, and group B was injected atropine 0.5 mg into the cervix.


RESULTS
(1) The mean time period from drug administration to full dilation of the cervix was (3.1 +/- 0.3) h in group A, and (4.4 +/- 0.4) h in group B (P < 0.01). (2) The disappearance ratio of cervical edema 2 h after drug administration in group A was 95.6%, while in group B it was 90.2% (P > 0.05); the mean dilatation of cervix between the 2 hours in group A was (4.3 +/- 0.2) cm, while in group B it was (2.5 +/- 0.3) cm (P < 0.01). (3) There were no obvious side effects in group A. While eight women in group B complained of thirst and 22 women had increased heart rate accompanied with elevated baseline FHR, which all recovered in about 60 minutes. (4) Vaginal delivery rate in group A was 95.7%, and 90.2% in group B (P > 0.05). (5) There was no statistically significant difference in the color of amniotic fluid, suffocation state and weight of the newborns between the two groups (P > 0.05). (6) There was no statistically significant difference in postpartum hemorrhage between the two groups, either (P > 0.05).


CONCLUSIONS
Spasfon can effectively improve cervical dilatation during labor and it is well tolerated by both mother and newborn.
Hao
Yan
Y
Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital University of Medical Science, Beijing 100025, China.
Zhai
Gui-rong
GR
Duan
Ai-hong
AH
D000282:Administration, Intravaginal; D000328:Adult; D001285:Atropine / Q000494:pharmacology*; D020070:Cervical Ripening / Q000187:drug effects; D002584:Cervix Uteri / Q000187:drug effects*; D036861:Delivery, Obstetric; D005260:Female; D006340:Heart Rate, Fetal; D006801:Humans; D007231:Infant, Newborn; D007747:Labor Stage, First / Q000187:drug effects; D007751:Labor, Induced; D010696:Phloroglucinol / Q000494:pharmacology*; D011247:Pregnancy; D013997:Time Factors; D014590:Uterine Contraction / Q000187:drug effects*
D001285:Atropine; D010696:Phloroglucinol